At a glance
ClinicalIndex Comparison RecordN/ACompleted· 22 enrolled
Drug / intervention
Participants received a Neurostimulator, which was used to map the pudendal nervedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pudendal Nerve Mapping Towards Improved Neuromodulation for Urinary Retention
In Brief
A clinical study evaluating Participants received a Neurostimulator, which was used to map the pudendal nerve for Urinary Retention and Underactive Bladder. Completed, enrolled 22 participants across 1 site.
Detailed Summary
This study is to map the pudendal nerve. In this study the researchers will examine subjects who are already receiving an implanted stimulator at their pudendal nerve as part of their normal clinical care.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUrinary Retention, Underactive Bladder
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedJan 2020
Enrollment StartSep 2020
Primary CompletionJun 2023
TodayJul 2026
First PostedJan 22, 2020
Enrollment StartSep 14, 2020
Primary CompletionJun 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 6.4 years ago
Interventions
Participants received a Neurostimulator, which was used to map the pudendal nervedevice
Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.